An update on allergen immunotherapy and asthma

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 1, 2014, Pages 109-117

  Compalati, Enrico ^a   Braido, Fulvio ^a   Canonica, Giorgio W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

allergen specific immunotherapy; asthma; efficacy; evidence

Indexed keywords

ALLERGEN; BIRCH ALLERGEN; BUDESONIDE; CORTICOSTEROID; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; INTERLEUKIN 10; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; STEROID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ASTHMA; BIRCH; BRONCHUS HYPERREACTIVITY; CD4+ CD25+ T LYMPHOCYTE; CHILDHOOD DISEASE; DERMATOPHAGOIDES; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; MAST CELL DEGRANULATION; POSTMARKETING SURVEILLANCE; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; STEROID THERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY;

ADMINISTRATION, SUBLINGUAL; ADULT; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 84890099883     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000016     Document Type: Review

References (72)

1. Malling H, Weeke B. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993; 48:9-35
2. Freeman J. Vaccination against hay fever: Report of results during the first three years. Lancet 1914; 1:1178
3. Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: Therapeutical vaccines for allergic diseases. Allergy 1998; 53:1-42
4. Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: Implications for current treatment strategies. Clin Exp Immunol 2009; 158:260-271
5. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2001; 113:1129-1136
6. Passalacqua G, Canonica GW. Sublingual immunotherapy: Update 2006
7. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl):S147-S334
8. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report (publication No. 02-3659). Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2008
9. Slats AM, Janssen K, van Schadewick A, et al. Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma. J Allergy Clin Immunol 2008; 121:1196-1202
10. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-Term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997
11. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: An open, parallel, comparative trial. Clin Exp Allergy 1997; 27:1279-1284
12. Akdis M. Immune tolerance in allergy. Curr Opin Immunol 2009; 21:700-707
13. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119:780-791
14. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-1261
15. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-677
16. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92 (1 Pt 1):6-15
17. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129-1136
18. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8:CD001186
19. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl): S1-55
20. Halken S, Lau S. New visions in specific immunotherapy in children: An iPAC summary and future trends. Pediatr Allergy Immunol 2008; 19 (Suppl. 19): 60-70
21. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336:324-331
22. Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: Effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999; 103:609-614
23. Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J Asthma 2009; 46:322-334
24. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 12:CD002893
25. Calamita Z, Saconato H, Pela AB, Atallah NA. Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized clinical trials. Allergy 2006; 61:1162-1172
26. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children: Meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2006; 97:141-148
27. Penagos M, Passalacqua G, Compalati E. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609
28. Nieto A, Mazon A, Pamies R, et al. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-Analyses. J Allergy Clin Immunol 2009; 124:157-161
29. Compalati E, Penagos M, Tarantini F. Specific immunotherapy for respiratory allergy: State of the art according to current meta-Analyses. Ann Allergy Asthma Immunol 2009; 102:22-28
30. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 (Suppl 91):1-59
31. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-190
32. Mösges R, Graute V, Christ H, et al. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol 2010; 21:1135-1138
33. Roger A, Justicia JL, Navarro LÁ, et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol 2011; 154:69-75
34. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012; 67:302-311
35. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: A double-blind placebo-controlled study. Allergy 1999; 54:249-260
36. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of long-Term sublingual immunotherapy in asthmatic children sensitized to mite: A double-blind study. Allergy 2000; 55:842-849
37. Pajno G, Vita D, Parmiani S, et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33:1641-1647
38. Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-Dose mite extracts in asthma: A multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100:1374-1383
39. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-415
40. Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-Avoidance measures. Pediatr Allergy Immunol 2007; 18:47-57
41. Stelmach I, Kaczmarek-Wožniak J, Majak P, et al. Efficacy and safety of highdoses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009; 39:401-408
42. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-173
43. Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy 2011; 66 (Suppl 95):55-56
44. ClinicalTrials.gov Identifier: NCT01433523. Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial. http://clinicaltrials.gov/show/NCT01433523. [Accessed 08 March 2013
45. Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62 (Suppl 84):1-41
46. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324
47. Bousquet PJ, Calderón MA, Demoly P, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011; 127:49-56
48. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-Term preventive effect on seasonal and perennial asthma: 10-year followup on the PAT study. Allergy 2007; 62:943-948
49. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857
50. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow up on the PAT study: Specific immunotherapy and long-Term prevention of asthma in children. Allergy 2006; 61:865-869
51. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A ten year prospective study. Clin Exp Allergy 2003; 33:206-210
52. Marogna M, Spadolini I, Massolo A, et al. Long-Term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009; 102:69-75
53. Stelmach I, Sobocińska A, Majak P, et al. Comparison of the long-Termefficacy of 3-And 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012; 109:274-278
54. Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo controlled, double-blind, double-Dummy study. Int Arch Allergy Immunol 2012; 157:e288-e298
55. Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, et al. Comparative effect of precoseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012; 67:312-320
56. Wahn U, Klimek L, Ploszczuk A, et al. High-Dose sublingual immunotherapy with single-Dose aqueous grass pollen extract in children is effective and safe: A double blind, placebo-controlled study. J Allergy Clin Immunol 2012; 130:886-893
57. Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: A retrospective, observational study. Int J Immunopathol Pharmacol 2012; 25:193-206
58. Zheng BQ, Wang GL, Yang S. Efficacy of specific sublingual immunotherapy with dermatophagoides farinae drops in the treatment of cough variant asthma in children. Zhongguo Dang Dai Er Ke Za Zhi 2012; 14:585-588
59. Marogna M, Braidi C, Bruno ME, et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: A real-life randomised trial. Allergol Immunopathol (Madr) 2013; 41:216-224
60. De Castro G, Zicari AM, Indinnimeo L, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. Eur Rev Med Pharmacol Sci 2013; 17:2225-2231
61. Peng W, Liu E. Factors influencing the response to specific immunotherapy for asthma in children aged 5-16 years. Pediatr Int 2013. doi: 10.1111/ ped.12175. [Epub ahead of print
62. Rosewich M, Arendt S, El Moussaoui S, et al. Bronchial allergen provocation: A useful method to assess the efficacy of specific immunotherapy in children. Pediatr Allergy Immunol 2013; 24:434-440
63. Costa JC, Plácido JL, Silva JP, et al. Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-Dust mites (D. pteronyssinus) on inhaled steroid therapy. Allergy 1996; 51:238-244
64. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial. Allergy 2006; 61:843-848
65. Zielen S, Kardos P, Madonini E. Steroid-sparing effect of subcutaneous SQstandardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. J Allergy Clin Immunol 2010; 126:942-949
66. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM, Regione Veneto Study Group on the 'Effect of immunotherapy in allergic asthma'. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113:643-649
67. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336:324-331
68. Ozdemir C, Yazi D, Gocmen I, et al. Efficacy of long-Term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-Allergic children with asthma. Pediatr Allergy Immunol 2007; 18:508-515
69. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. JAMA 2013; 309:1278-1288
70. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review. Pediatrics 2013; 131:1155-1167
71. Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: Comparative effectiveness review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Mar. Report No.: 13-EHC061-EF. AHRQ Comparative Effectiveness Reviews; 2013
72. Atkins D, Best D, Briss PA, et al., GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:1490